BAN2401
Alzheimer's Disease
Key Facts
About BioArctic
BioArctic is a research-driven biopharma company with a mission to develop transformative treatments for neurodegenerative diseases. Its strategic partnership with Eisai led to the landmark approval and commercialization of lecanemab for Alzheimer's, providing a foundational revenue stream. The company's core strategy is to leverage its proprietary BrainTransporter™ platform to build a diversified pipeline of next-generation biologics for Parkinson's and ALS, while continuing to advance its Alzheimer's franchise.
View full company profileAbout BioArctic AB
BioArctic AB is a research-intensive Swedish biopharma focused on translating novel insights into protein aggregation pathology into transformative treatments for neurodegenerative diseases. Its strategic triumph is the Eisai-partnered anti-amyloid beta protofibril antibody lecanemab (Leqembi®), which achieved FDA approval in 2023, validating the company's core scientific thesis. The company's strategy balances revenue from this landmark partnership with advancing a wholly-owned pipeline targeting alpha-synuclein in Parkinson's disease, leveraging its proprietary BrainTransporter® platform to enhance drug delivery to the brain. With a market cap nearing $28 billion, BioArctic stands as a premier European biotech success story.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| itMSCs | Stemedica Cell Technologies | Clinical Development |
| Aucuba-001 | Aucuba Sciences | Preclinical |
| ALTA Drug Series | Alteron Therapeutics | Preclinical |
| NTRX-07 | NeuroTherapia | Phase 2 |
| 3D Neuronal Disease Models | BioTalentum | Research |
| Not Publicly Disclosed | Cerecin | Phase 1/2 |
| Not Specified | Asceneuron | Not Disclosed |